RAPPORT - SFRMS

— 280 —F. BIBLIOGRAPHIE1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Sampling and methods ofthe European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl2004:8-20.2. Lepine JP, Gasquet I, Kovess V, Arbabzadeh-Bouchez S, Negre-Pages L, Nachbaur G, et al. [Prevalence andcomorbidity of psychiatric disorders in the French general population]. Encephale 2005;31:182-94.3. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mentaldisorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)project. Acta Psychiatr Scand Suppl 2004:21-7.4. Kovess V, Brugha T, Carta MG, Lehtinen V. The state of mental health in the European Union. EuropeanCommunity, 2004:79.5. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity,and unmet need for treatment of mental disorders in the World Health Organization World Mental HealthSurveys. JAMA 2004;291:2581-90.6. Bellamy V, Roelandt J, Caria A. Troubles mentaux et représentations de la santé mentale: premiers résultatsde l'enquête Santé Mentale en Population Générale. Etudes et Résultats, DREES 2004;n°347:1-12.7. Ritchie K, Artero S, Beluche I, Ancelin ML, Mann A, Dupuy AM, et al. Prevalence of DSM-IV psychiatricdisorder in the French elderly population. Br J Psychiatry 2004;184:147-52.8. Expertise Collective INSERM. Données épidémiologiques. Troubles mentaux : dépistage et prévention chezl'enfant. In: INSERM, 2002.9. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Psychotropic drugutilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)project. Acta Psychiatr Scand Suppl 2004:55-64.10. Gasquet I, Negre-Pages L, Fourrier A, Nachbaur G, El-Hasnaoui A, Kovess V, et al. [Psychotropic drug useand mental psychiatric disorders in France; results of the general population ESEMeD/MHEDEA 2000epidemiological study]. Encephale 2005;31:195-206.11. Le Pape A, Lecomte T. Prévalence et prise en charge médicale de la dépression en 1996-1997. Questionsd’économie de la santé, CREDES 1999;n°21:1-6.12. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H, et al. Patterns and correlates ofbenzodiazepine use in the French general population. Eur J Clin Pharmacol 2004;60:523-9.13. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany,Italy, and the United Kingdom. J Clin Psychiatry 2002;63:817-25.14. Ohayon M, Caulet M, Lemoine P. [The elderly, sleep habits and use of psychotropic drugs by the Frenchpopulation]. Encephale 1996;22:337-50.15. Kuhn F, Pedailles S, Pull MT, Guyon FX, Thielly P. Adéquation à l'autorisation de mise sur le marché desinstaurations de traitement par inhibiteurs spécifiques de la recapture de sérotonine. Revue Médicale del'Assurance Maladie 2006;37:1-7.16. Healy D, Langmaak C, Savage M. Suicide in the course of the treatment of depression. J Psychopharmacol1999;13:94-9.17. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment.Am J Psychiatry 1990;147:207-10.18. Beasley CM, Jr., Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr., Heiligenstein JH, et al.Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991;303:685-92.19. The American College of Neuropsychopharmacology. Preliminary report of the task force on SSRIs andsuicidal behavior in youth, 2004.20. Food and Drug Administration. Antidepressant use in children, adolescents, and adults.http://www.fda.gov/cder/drug/antidepressants/default.htm ed.: FDA Website.